论文部分内容阅读
目的观察醒脑静在佐治肺性脑病中的临床效果。方法将48例肺性脑病患者随机分为对照组和治疗组。对照组患者给予氧疗、平喘、祛痰、利尿、强心、抗感染、呼吸兴奋剂及糖皮质激素等常规治疗;治疗组在此基础上采用醒脑静30 ml 静脉滴注。对两组临床疗效进行对比分析。结果总有效率:对照组65.21%,治疗组92.00%,差异有显著性(P<0.05);治疗组意识恢复时间65.00±28.54 h,比对照组的80.12±29.58 h 平均提前38.57 h(P<0.01);两组治疗后 SPO_2、pH 值、PaO_2、PaCO_2均有改善(P<0.05);且治疗组明显优于对照组(P<0.01)。结论醒脑静是防治肺性脑病安全有效的药物。
Objective To observe the clinical effect of Xingnaojing in treating pulmonary pulmonary encephalopathy. Methods 48 patients with pulmonary encephalopathy were randomly divided into control group and treatment group. Patients in the control group were given conventional therapy of oxygen therapy, antiasthmatic, expectorant, diuretic, cardiac, anti-infective, respiratory stimulant and glucocorticoid. On the basis of this, the treatment group was given intravenous drip of 30 ml Xingnaojing. The clinical efficacy of the two groups were compared. Results The total effective rate was 65.21% in the control group and 92.00% in the treatment group, with significant difference (P <0.05). The recovery time in the treatment group was 65.00 ± 28.54 h, which was 38.57 h earlier than that in the control group (80.12 ± 29.58 h, P < 0.01). The SPO_2, pH, PaO_2, PaCO_2 in both groups were improved after treatment (P <0.05), and the treatment group was significantly better than the control group (P <0.01). Conclusion Xingnaojing is a safe and effective drug for the prevention and treatment of pulmonary encephalopathy.